Literature DB >> 26457961

T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.

Armen Mardiros1, Stephen J Forman, Lihua E Budde.   

Abstract

PURPOSE OF REVIEW: The purpose of this article is to discuss the rationale of targeting CD123 using chimeric antigen receptor (CAR) T cells for the treatment of leukemia. RECENT
FINDINGS: CD123 is a leukemia-associated antigen that expresses at high levels in leukemic stem cells and leukemic blasts and low level in normal hematopoietic stem/progenitor cells. Immune-based therapies targeting CD123 are being developed. Preclinical data suggest that CD123 CAR T cells exhibit potent antileukemic activity and various impacts on normal hematopoiesis.
SUMMARY: CD123 is an attractive surface target for novel antileukemic therapies. CD123 CAR T-cell-based immunotherapy is a promising treatment for patients with relapsed or refractory acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26457961      PMCID: PMC4624420          DOI: 10.1097/MOH.0000000000000190

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  34 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

4.  Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues.

Authors:  S Huang; Z Chen; J F Yu; D Young; A Bashey; A D Ho; P Law
Journal:  Stem Cells       Date:  1999       Impact factor: 6.277

5.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Authors:  Eva Nievergall; Hayley S Ramshaw; Agnes S M Yong; Mark Biondo; Samantha J Busfield; Gino Vairo; Angel F Lopez; Timothy P Hughes; Deborah L White; Devendra K Hiwase
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

7.  Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.

Authors:  Quan-shun Wang; Yao Wang; Hai-yan Lv; Qing-wang Han; Hui Fan; Bo Guo; Li-li Wang; Wei-dong Han
Journal:  Mol Ther       Date:  2014-09-01       Impact factor: 11.454

8.  Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.

Authors:  Jennifer F Yamamoto; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2007-12-07       Impact factor: 2.506

Review 9.  Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.

Authors:  Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Taiga Nishihori; Rami A Mahfouz; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-05       Impact factor: 5.742

10.  A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

Authors:  Simon Z He; Samantha Busfield; David S Ritchie; Mark S Hertzberg; Simon Durrant; Ian D Lewis; Paula Marlton; Andrew J McLachlan; Ian Kerridge; Kenneth F Bradstock; Glen Kennedy; Andrew W Boyd; Trina M Yeadon; Angel F Lopez; Hayley S Ramshaw; Harry Iland; Simone Bamford; Megan Barnden; Mark DeWitte; Russell Basser; Andrew W Roberts
Journal:  Leuk Lymphoma       Date:  2014-11-20
View more
  22 in total

Review 1.  Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Authors:  Sisi Zheng; Mukta Asnani; Andrei Thomas-Tikhonenko
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

2.  A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.

Authors:  Samuel John; Heyu Chen; Mi Deng; Xun Gui; Guojin Wu; Weina Chen; Zunling Li; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Mol Ther       Date:  2018-08-07       Impact factor: 11.454

3.  NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Authors:  David A Sallman; Jason Brayer; Elizabeth M Sagatys; Caroline Lonez; Eytan Breman; Sophie Agaugué; Bikash Verma; David E Gilham; Frédéric F Lehmann; Marco L Davila
Journal:  Haematologica       Date:  2018-04-27       Impact factor: 9.941

4.  Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.

Authors:  Nicole M Cruz; Mayumi Sugita; Nathan Ewing-Crystal; Linda Lam; Roman Galetto; Agnes Gouble; Julianne Smith; Duane C Hassane; Gail J Roboz; Monica L Guzman
Journal:  Leuk Lymphoma       Date:  2017-08-10

5.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

6.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

7.  Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics.

Authors:  Haibin Wu; Meng Wang; Bo Dai; Yanmin Zhang; Ying Yang; Qiao Li; Mingyue Duan; Xi Zhang; Xiaomei Wang; Anmao Li; Liyu Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling.

Authors:  Xia Fang; Chiqi Chen; Fangzhen Xia; Zhuo Yu; Yaping Zhang; Feifei Zhang; Hao Gu; Jiangbo Wan; Xiaocui Zhang; Wei Weng; Cheng Cheng Zhang; Guo-Qiang Chen; Aibing Liang; Li Xie; Junke Zheng
Journal:  J Hematol Oncol       Date:  2016-11-17       Impact factor: 17.388

Review 9.  Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.

Authors:  Huan-Huan Sha; Dan-Dan Wang; Da-Li Yan; Yong Hu; Su-Jin Yang; Si-Wen Liu; Ji-Feng Feng
Journal:  Biosci Rep       Date:  2017-01-27       Impact factor: 3.840

10.  Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.

Authors:  Haruko Tashiro; Tim Sauer; Thomas Shum; Kathan Parikh; Maksim Mamonkin; Bilal Omer; Rayne H Rouce; Premal Lulla; Cliona M Rooney; Stephen Gottschalk; Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-07-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.